Progyny Chief Operating Officer Melissa Cummings Executes Stock Transactions Under Prearranged Trading Plan

Restricted Stock Unit Vesting and Withholding Tax Treatment

On July 14, 2026, Cummings received 1,193 shares of Progyny common stock through the vesting of restricted stock units, with an attributed price of $31.98 per share. The disclosure indicates that these shares were withheld for payment of withholding taxes upon the vesting of the restricted stock units granted to the reporting person. This is a standard practice in equity compensation arrangements, where companies retain shares at vesting to satisfy tax withholding obligations on behalf of executives. The net effect of this transaction increased Cummings's direct beneficial ownership position in the company's common stock.

Restricted stock unit programs are commonly used by public companies to align executive compensation with long-term shareholder value creation. The vesting of these units represents the conversion of deferred compensation into actual company shares, subject to applicable tax withholding requirements. The transaction demonstrates the ongoing equity participation of Progyny's executive leadership in the company's financial performance and shareholder returns.

Prearranged Stock Sales Under Rule 10b5-1 Trading Plan

On the same trading day, Cummings sold 2,244 shares of Progyny common stock at a price of $31.60 per share pursuant to a Rule 10b5-1 trading plan that was established on December 19, 2025. Rule 10b5-1 trading plans allow company insiders to establish predetermined schedules for buying or selling securities while avoiding potential concerns about trading on material nonpublic information. The establishment of such plans in advance demonstrates compliance with securities regulations and provides transparency to investors regarding executive stock transactions.

The timing and volume of share sales executed under a 10b5-1 plan are established well in advance of the actual transactions, removing discretion from the executive at the time of execution. This regulatory framework protects both the company and its officers by creating a clear record that trading decisions were made without reference to confidential corporate developments. The fact that Cummings's sale occurred at $31.60 per share, slightly below the vesting price of $31.98, provides a snapshot of market conditions on July 14, 2026.

Net Changes in Beneficial Ownership Position

The aggregate effect of both transactions on July 14, 2026 resulted in a net reduction of Cummings's share holdings. She acquired 1,193 shares through restricted stock unit vesting and disposed of 2,244 shares through the prearranged trading plan, producing a net decrease of 1,051 shares from these two transactions. Following these activities, the disclosure shows that Cummings maintained beneficial ownership of 69,934 shares of Progyny common stock in direct ownership form, with no indirect beneficial ownership interests reported.

Changes in insider ownership positions are tracked closely by market participants as potential indicators of executive confidence in company prospects. The concurrent acquisition through vesting and sale through a predetermined plan represents a routine rebalancing of compensation and portfolio exposure typical of executive equity management. The disclosure of these transactions provides investors with visibility into the equity stakes held by senior management and the timing of executive trading activity.

Progyny's Business Model and Market Position

Progyny, Inc. operates as a fertility and family benefits platform serving employers and their employees across the United States. The company provides comprehensive fertility, family planning, and related healthcare benefits designed to help employers attract and retain talent while supporting employee family-building goals. Progyny's platform includes access to fertility treatments, family planning services, pregnancy support, and related benefits, differentiating it in the employee benefits marketplace where reproductive health benefits have become increasingly important to workforce competitiveness.

As a NASDAQ-listed company, Progyny generates revenue through employer subscription models and administrative fees associated with its benefits platform. The company's growth has been driven by increasing employer demand for comprehensive family benefits and the expanding recognition of fertility coverage as a key employee retention tool. The executive trading activity reported by Chief Operating Officer Cummings reflects participation in a company whose compensation philosophy includes equity incentives tied to long-term operational performance and shareholder value creation.

Timing and Compliance Framework for Executive Trading

The disclosure filed on July 16, 2026 reports trading activity that occurred on July 14, 2026, which is consistent with standard regulatory timelines requiring insiders to file beneficial ownership statements within two business days of transaction execution. The checkbox indicating that the stock transaction was made pursuant to a Rule 10b5-1 contract, instruction, or written plan demonstrates Progyny's adherence to regulatory best practices regarding insider trading compliance. This certification provides assurance to market participants that the transactions were executed under pre-established parameters unrelated to material nonpublic information.

The regulatory framework governing insider transactions serves multiple purposes, including preventing trading based on confidential information, providing transparency to shareholders about management stakes in the company, and creating an auditable record of executive investment decisions. By establishing the 10b5-1 plan in December 2025, Cummings created a clear separation between the investment decision and the execution of that decision in July 2026. This structure is commonly employed by corporate executives seeking to manage their equity exposure and diversify their personal portfolios while maintaining compliance with securities regulations.

Direct Beneficial Ownership and Reporting Status

Following the July 14, 2026 transactions, the disclosure confirms that Cummings holds 69,934 shares of Progyny common stock in direct beneficial ownership, with no portion held through indirect ownership structures such as trusts, family entities, or other arrangements. The direct ownership designation indicates that Cummings has immediate and full control over these shares without any intermediary. This level of transparency regarding the form of ownership supports investors' ability to assess the genuine commitment of company leadership to shareholder value creation.

The distinction between direct and indirect beneficial ownership is significant in securities law because it reflects the nature and degree of control an officer or director exercises over company shares. Direct ownership typically represents the most straightforward alignment between executive financial interests and shareholder outcomes. The reporting confirms that Cummings's entire 69,934-share position is held directly, indicating unencumbered personal ownership of a meaningful stake in the company.

Officer Title and Governance Disclosure

Melissa B. Cummings is identified in the disclosure as Chief Operating Officer of Progyny, Inc., reflecting her senior executive role in the company's operational management. As COO, Cummings would typically be responsible for day-to-day operational execution, organizational management, and implementation of strategic initiatives developed by the executive leadership team. The disclosure confirms her status as an officer of the company, which triggers reporting obligations under Section 16(a) of the Securities Exchange Act of 1934, ensuring public visibility into her trading activities.

Officer-level insiders have access to material nonpublic information related to company performance, strategic initiatives, financial results, and other sensitive business matters. This heightened information access is the reason why securities law requires detailed public reporting of their stock transactions. By establishing a Rule 10b5-1 plan months in advance of the actual trading activity, Cummings demonstrated appropriate compliance with the regulatory framework designed to prevent insider trading concerns while allowing executives to manage their personal investment portfolios.

Market Context and Stock Price Indicators

The disclosed trading prices provide a market snapshot from July 14, 2026. Shares acquired through restricted stock unit vesting were attributed a price of $31.98 per share, while shares sold under the 10b5-1 plan executed at $31.60 per share. The modest difference between these prices reflects intraday market movements or potentially different transaction execution times during the trading day. These price points provide context for market conditions at the time the transactions occurred, though they do not necessarily indicate directional sentiment from the executive regarding future stock performance.

The price differential between the vesting transaction and the sale is relatively narrow, suggesting stable market conditions on the transaction date. Executives often view restricted stock unit vesting as a form of deferred compensation rather than a discretionary investment decision, while sales under prearranged 10b5-1 plans typically reflect predetermined portfolio rebalancing decisions made months earlier. The pricing in both transactions reflects ordinary market conditions rather than any special circumstances affecting the stock on July 14, 2026.

Investor Considerations and Disclosure Transparency

The disclosure of insider transactions by senior officers like the Chief Operating Officer provides investors with material information about executive confidence levels, portfolio positioning, and compliance with securities regulations. Regular review of insider transaction disclosures can help investors understand whether company leadership is adding to or reducing their equity stakes, though individual transactions must be interpreted within the context of broader compensation arrangements and predetermined trading plans. The Rule 10b5-1 framework ensures that such transactions are made according to prearranged schedules rather than in response to short-term market movements or confidential business information.

Investors monitoring insider transactions should consider whether officers are establishing new 10b5-1 plans (potentially indicating intentions to diversify holdings), or executing predetermined plans established months earlier (typically reflecting routine portfolio management rather than changed confidence in the company). The disclosure demonstrates Progyny's commitment to regulatory compliance and transparency in executive equity transactions. Market participants may continue to monitor insider trading patterns as one data point among many in evaluating company performance and management commitment to shareholder value creation.